AccuGenomics is driven to improve the accuracy and performance of clinical sequencing for better patient outcomes. The rapid pace of innovation in sequencing-based diagnostics continues to push the limits of detectability for low abundance biomarkers, increasing the need to demonstrate the analytical performance of these tests for patients and healthcare providers. AccuGenomics is actively developing technology solutions that enable test developers and implementers to demonstrate the highest performance levels of their assay.
AccuGenomics improves the diagnostic accuracy and confidence in today’s next generation precision medicine assays through the use of their exclusively-licensed SNAQ™-SEQ internal standards technology. SNAQ-SEQ enables a host of high-sensitive NGS applications including improved ctDNA detection of rare variants; rapid adventitious agent detection in cell therapy manufacturing including CAR-T cells and genetically-engineered stem cells.